SG Americas Securities LLC Makes New Investment in Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX)

SG Americas Securities LLC acquired a new stake in Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 23,822 shares of the company’s stock, valued at approximately $552,000. SG Americas Securities LLC owned 0.05% of Forma Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. WINTON GROUP Ltd bought a new stake in Forma Therapeutics in the third quarter valued at approximately $239,000. Virginia Retirement Systems ET AL boosted its holdings in shares of Forma Therapeutics by 8.9% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 18,400 shares of the company’s stock worth $427,000 after buying an additional 1,500 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Forma Therapeutics by 71.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 91,487 shares of the company’s stock worth $2,277,000 after buying an additional 38,137 shares in the last quarter. Integral Health Asset Management LLC bought a new position in shares of Forma Therapeutics during the 2nd quarter worth approximately $1,120,000. Finally, Morgan Stanley raised its position in shares of Forma Therapeutics by 5.7% during the second quarter. Morgan Stanley now owns 108,462 shares of the company’s stock worth $2,699,000 after purchasing an additional 5,833 shares during the period. 83.18% of the stock is owned by institutional investors.

A number of equities research analysts recently commented on FMTX shares. SVB Leerink reissued a “buy” rating and issued a $54.00 price target on shares of Forma Therapeutics in a research report on Monday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Forma Therapeutics in a research note on Monday, October 18th. Finally, Zacks Investment Research upgraded shares of Forma Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Monday, January 3rd. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $48.20.

FMTX stock opened at $11.75 on Friday. Forma Therapeutics Holdings, Inc. has a fifty-two week low of $11.08 and a fifty-two week high of $42.88. The business’s 50 day moving average price is $15.18 and its two-hundred day moving average price is $19.99. The company has a market capitalization of $557.01 million, a price-to-earnings ratio of -3.59 and a beta of -0.27.

Forma Therapeutics (NASDAQ:FMTX) last posted its quarterly earnings results on Friday, November 12th. The company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.05. During the same period in the previous year, the company posted ($0.67) earnings per share. Research analysts forecast that Forma Therapeutics Holdings, Inc. will post -3.36 earnings per share for the current year.

About Forma Therapeutics

Forma Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.

Read More: Quick Ratio

Institutional Ownership by Quarter for Forma Therapeutics (NASDAQ:FMTX)

Receive News & Ratings for Forma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.